甲状腺结节TI-RADS分级解读

2020-03-31 网络 网络

TI-RADS(Thyroid imaging reporting and data system)即甲状腺影像报告和数据系统。依据五个甲状腺结节恶性特征进行分级:1、实性结节;2、低回声或极低回声;

TI-RADS(Thyroid imaging reporting and data system)即甲状腺影像报告和数据系统。依据五个甲状腺结节恶性特征进行分级:1、实性结节;2、低回声或极低回声;3、分叶或边缘不规则;4、砂砾样钙化;5、纵横比≥1 。

TI-RADS分级 0 级

资料不全,需结合其他检查再评估。

TI-RADS分级 1 级

阴性,正常超声表现,常规体检(1年1次)。

TI-RADS分级 2 级

良性病变,恶性可能为0。

特点:

无回声(囊性)为主,界清,回声可均匀或不均匀,内可伴点状高回声,可有血流。如:囊肿,海绵状结节,腺瘤囊性变等。

甲状腺内以囊性为主的囊实性团块,其内可见海绵样回声。

TI-RADS分级 3 级

可能良性病变(<5%恶性)

特点:

边缘光整,实性为主,可伴有蛋壳样钙化或粗大钙化如:桥本甲状腺炎、腺瘤等。

甲状腺内实性团块,边缘光整,形态规则,内部回声均匀。

TI-RADS分级 4 级

可疑恶性(5%-80%恶性)

4A特点:

实性为主结节,形态规则或不规则,边界清或不清,无微钙化。如:腺瘤、亚甲炎等。

4B特点:

实性为主结节,边界不清,伴有微钙化。如:乳头状癌、滤泡状癌。

甲状腺内低回声结节,形态欠规则,边缘可见短毛刺,无微钙化,TI-RADS分级4A级。

甲状腺内两个低回声团块,界限局部欠清,形态不规则,内部回声不均匀,其内可见微钙化,TI-RADS分级4B级。

TI-RADS分级 5 级

高度怀疑恶性(>80%恶性)

特点:

实性结节,形态不规则,边界不清,血流丰富,微钙化如:乳头状癌、髓样癌等。

甲状腺内实性团块,形态不规则,边界欠清,其内可见典型微钙化,弹性评分4分。

TI-RADS分级 6 级

活检证实为恶性

是新增加的类型,用在活检证实为恶性,但还未进行治疗的影像评价上。

甲状腺实性团块及同侧颈部淋巴结二维超声典型恶性征象,经细针穿刺细胞活检后病理结果:考虑为甲状腺乳头状癌及同侧淋巴结甲状腺乳头状癌转移。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1075091, encodeId=a8e310e5091c7, content=4级恶性率是5-20%,5级是大于20%吧!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29be5722347, createdName=ms3000001050748197, createdTime=Mon Nov 29 15:03:34 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813482, encodeId=c21e81348246, content=<a href='/topic/show?id=e6956990e9e' target=_blank style='color:#2F92EE;'>#甲状腺结节#</a><a href='/topic/show?id=fe0110382ee5' target=_blank style='color:#2F92EE;'>#TI-RADS分级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69907, encryptionId=e6956990e9e, topicName=甲状腺结节), TopicDto(id=103827, encryptionId=fe0110382ee5, topicName=TI-RADS分级)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:58:22 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029525, encodeId=498720295255b, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Oct 01 23:24:30 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746584, encodeId=795d1e46584d7, content=<a href='/topic/show?id=89431e42974' target=_blank style='color:#2F92EE;'>#TI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17429, encryptionId=89431e42974, topicName=TI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca435789970, createdName=sjzlzc019, createdTime=Thu Apr 09 05:24:30 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792992, encodeId=863c1e9299288, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Wed Jul 22 15:24:30 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381185, encodeId=d968381185e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Tue Mar 31 08:20:16 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
    2021-11-29 ms3000001050748197

    4级恶性率是5-20%,5级是大于20%吧!!!!!

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1075091, encodeId=a8e310e5091c7, content=4级恶性率是5-20%,5级是大于20%吧!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29be5722347, createdName=ms3000001050748197, createdTime=Mon Nov 29 15:03:34 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813482, encodeId=c21e81348246, content=<a href='/topic/show?id=e6956990e9e' target=_blank style='color:#2F92EE;'>#甲状腺结节#</a><a href='/topic/show?id=fe0110382ee5' target=_blank style='color:#2F92EE;'>#TI-RADS分级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69907, encryptionId=e6956990e9e, topicName=甲状腺结节), TopicDto(id=103827, encryptionId=fe0110382ee5, topicName=TI-RADS分级)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:58:22 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029525, encodeId=498720295255b, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Oct 01 23:24:30 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746584, encodeId=795d1e46584d7, content=<a href='/topic/show?id=89431e42974' target=_blank style='color:#2F92EE;'>#TI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17429, encryptionId=89431e42974, topicName=TI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca435789970, createdName=sjzlzc019, createdTime=Thu Apr 09 05:24:30 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792992, encodeId=863c1e9299288, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Wed Jul 22 15:24:30 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381185, encodeId=d968381185e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Tue Mar 31 08:20:16 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1075091, encodeId=a8e310e5091c7, content=4级恶性率是5-20%,5级是大于20%吧!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29be5722347, createdName=ms3000001050748197, createdTime=Mon Nov 29 15:03:34 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813482, encodeId=c21e81348246, content=<a href='/topic/show?id=e6956990e9e' target=_blank style='color:#2F92EE;'>#甲状腺结节#</a><a href='/topic/show?id=fe0110382ee5' target=_blank style='color:#2F92EE;'>#TI-RADS分级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69907, encryptionId=e6956990e9e, topicName=甲状腺结节), TopicDto(id=103827, encryptionId=fe0110382ee5, topicName=TI-RADS分级)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:58:22 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029525, encodeId=498720295255b, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Oct 01 23:24:30 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746584, encodeId=795d1e46584d7, content=<a href='/topic/show?id=89431e42974' target=_blank style='color:#2F92EE;'>#TI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17429, encryptionId=89431e42974, topicName=TI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca435789970, createdName=sjzlzc019, createdTime=Thu Apr 09 05:24:30 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792992, encodeId=863c1e9299288, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Wed Jul 22 15:24:30 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381185, encodeId=d968381185e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Tue Mar 31 08:20:16 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1075091, encodeId=a8e310e5091c7, content=4级恶性率是5-20%,5级是大于20%吧!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29be5722347, createdName=ms3000001050748197, createdTime=Mon Nov 29 15:03:34 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813482, encodeId=c21e81348246, content=<a href='/topic/show?id=e6956990e9e' target=_blank style='color:#2F92EE;'>#甲状腺结节#</a><a href='/topic/show?id=fe0110382ee5' target=_blank style='color:#2F92EE;'>#TI-RADS分级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69907, encryptionId=e6956990e9e, topicName=甲状腺结节), TopicDto(id=103827, encryptionId=fe0110382ee5, topicName=TI-RADS分级)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:58:22 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029525, encodeId=498720295255b, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Oct 01 23:24:30 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746584, encodeId=795d1e46584d7, content=<a href='/topic/show?id=89431e42974' target=_blank style='color:#2F92EE;'>#TI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17429, encryptionId=89431e42974, topicName=TI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca435789970, createdName=sjzlzc019, createdTime=Thu Apr 09 05:24:30 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792992, encodeId=863c1e9299288, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Wed Jul 22 15:24:30 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381185, encodeId=d968381185e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Tue Mar 31 08:20:16 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
    2020-04-09 sjzlzc019
  5. [GetPortalCommentsPageByObjectIdResponse(id=1075091, encodeId=a8e310e5091c7, content=4级恶性率是5-20%,5级是大于20%吧!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29be5722347, createdName=ms3000001050748197, createdTime=Mon Nov 29 15:03:34 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813482, encodeId=c21e81348246, content=<a href='/topic/show?id=e6956990e9e' target=_blank style='color:#2F92EE;'>#甲状腺结节#</a><a href='/topic/show?id=fe0110382ee5' target=_blank style='color:#2F92EE;'>#TI-RADS分级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69907, encryptionId=e6956990e9e, topicName=甲状腺结节), TopicDto(id=103827, encryptionId=fe0110382ee5, topicName=TI-RADS分级)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:58:22 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029525, encodeId=498720295255b, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Oct 01 23:24:30 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746584, encodeId=795d1e46584d7, content=<a href='/topic/show?id=89431e42974' target=_blank style='color:#2F92EE;'>#TI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17429, encryptionId=89431e42974, topicName=TI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca435789970, createdName=sjzlzc019, createdTime=Thu Apr 09 05:24:30 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792992, encodeId=863c1e9299288, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Wed Jul 22 15:24:30 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381185, encodeId=d968381185e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Tue Mar 31 08:20:16 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
    2020-07-22 江川靖瑶
  6. [GetPortalCommentsPageByObjectIdResponse(id=1075091, encodeId=a8e310e5091c7, content=4级恶性率是5-20%,5级是大于20%吧!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29be5722347, createdName=ms3000001050748197, createdTime=Mon Nov 29 15:03:34 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813482, encodeId=c21e81348246, content=<a href='/topic/show?id=e6956990e9e' target=_blank style='color:#2F92EE;'>#甲状腺结节#</a><a href='/topic/show?id=fe0110382ee5' target=_blank style='color:#2F92EE;'>#TI-RADS分级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69907, encryptionId=e6956990e9e, topicName=甲状腺结节), TopicDto(id=103827, encryptionId=fe0110382ee5, topicName=TI-RADS分级)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:58:22 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029525, encodeId=498720295255b, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Oct 01 23:24:30 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746584, encodeId=795d1e46584d7, content=<a href='/topic/show?id=89431e42974' target=_blank style='color:#2F92EE;'>#TI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17429, encryptionId=89431e42974, topicName=TI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca435789970, createdName=sjzlzc019, createdTime=Thu Apr 09 05:24:30 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792992, encodeId=863c1e9299288, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Wed Jul 22 15:24:30 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381185, encodeId=d968381185e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Tue Mar 31 08:20:16 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
    2020-03-31 1902498648_44512810

    0

相关资讯

石墨烯又一重磅研究:助力甲状腺结节治疗,拓展临床新应用

石墨烯被誉为“新材料之王”,是目前发现的最薄、强度最大、导电导热性能最强的一种新型纳米材料,是一种由碳原子以sp2杂化方式形成的蜂窝状平面薄膜,具备优良的电学、热学及光学等性能,不仅在涂料、发热散热、供暖、触控等领域实现初步应用,在医疗领域也被视为引发下一次医疗革命的关键。石墨烯治疗“甲状腺结节”重大医疗突破4月28日,由烯旺新材料科技股份有限公司(以下简称:烯旺科技)主办的医疗战略研讨会暨新品发

甲状腺结节是良性还是恶性?问5个问题就能搞清!

2万个甲状腺结节总结出的经验,5个问题搞定结节良恶性!

2018 KSThR共识声明:甲状腺结节乙醇消融治疗

有症状的甲状腺结节微创治疗很常见,乙醇消融治疗甲状腺囊性结节于20世纪90年代起开始实施,但是还没有全球性的共识和治疗。本文主要针对甲状腺结节乙醇消融治疗的相关内容提出指导建议。

Thyroid:二甲双胍在治疗甲状腺结节和胰岛素抵抗患者中的作用

由此可见,二甲双胍可诱导甲状腺结节和胰岛素抵抗患者甲状腺结节缩小和TSH、HOMA-IR水平降低。相反,未发现甲状腺体积变化。二甲双胍治疗甲状腺结节是否具有临床意义仍有待证实。

CLIN CANCER RES:阻止特异性DNA甲基化特征用于诊断甲状腺结节

由于恶性结节和良性结节之间细胞学特征的重叠,甲状腺癌常常难以诊断。从而导致许多没有癌症的患者不必要地切除了甲状腺。分子学方法虽然可以在细胞病理学诊断基础上得到一些改进,常常无法为甲状腺结节提供正确的诊断。这些方法的基础是癌症和周围正常甲状腺组织之间存在差异,并假设邻近组织与良性结节相同。然而,与周围正常组织相比,良性甲状腺结节可能包含可在癌症中发现的遗传改变。CLIN CANCER RES近期发表

甲状腺结节微波消融手术的常见问题解答

甲状腺结节是指甲状腺内出现的一个或多个结构异常团块。大多数甲状腺结节患者没有临床症状,常常是由本人无意中发现或医生在体检时触及,更多情况下是在超声或其它辅助检查时偶然被发现。根据2010年中国流行病学抽样调查,甲状腺结节在人群中总发病率为18.6%。如此庞大的数字并不仅仅源自疾病发病率的升高,更多还是归因于人们对健康的重视和体检的普及,特别是甲状腺超声等检查被列为健康体检的常规项目。使得以前“躲在